index.php

Resistance Test:

One of the fundamentals of InPheno is to offer services for the determination of HIV susceptibility applying a cutting edge proprietary technology platform called PhenoTectTM. PhenoTectTM is a new generation phenotypic analysis based on a replicative test format that delivers a direct answer to drug resistance and the unambiguous identification of therapy options. Since today's available HIV susceptibility assays, genotypic and phenotypic, deliver complimentary information, InPheno adopts a very pragmatic approach to best serve the treating physician in his therapy optimisation effort. The highly sensitive and real phenotype answer delivered by the recombinant virus assay PhenoTect overcomes the natural limits of the genotype-based predictions:

  • low sensitivity
  • analysis restricted to most prevalent average sequence only
  • difficulty in predicting the consequences of mutational interaction on phenotype
  • impossibility to detect novel mutations that confer resistance when no data available
  • Impossibility to detect resistance to new drugs and new drug classes. E.g. PhenotTect is testing susceptibility to Atazanavir (Zrivida, Bristol-Myers Squibb) and T-20 (Enfuvirtide, Roche Pharma)


    • A presentation describing characteristics of PhenoTect and its comparison to genotypic determination of HIV resistance is available upon simple request to info@inpheno.com PhenoTect therefore constitutes the best picture available and the closest to clinical conditions for the decision of the next steps for experienced and newly infected patients.

    Although InPheno has developed PhenoTect with state-of-the-art technologies, the ultimate aim is to directly assist the treating physician to take a rapid and knowledgeable decision; Therefore the PhenoTect Resistance report has been carefully designed in close collaboration with physicians to be directly readable and to contain maximum of information at the same time. Get a full size example of PhenoTect Resistance report.

    The main Assets of PhenoTect are:

  • Novel Replicative Test Format / 3 to 5 rounds of virus replication ' Closest to clinical conditions
  • Dissection of mixed populations/Comprehensive Profiling ' Detection of HIV variants down to 1%
  • Rapid Turnaround / 5 days propriatory assay format ' Timely decision making for treatment
  • Direct determination of drug-resistance / No interpretation algorithm needed ' Unambiguous identification of therapy options

    • Moreover, the PhenoTect platform is directly adaptable to newcoming drugs targeting other genes (test for fusion inhibitors already implemented, integrase inhibitors and transcriptional regulators in development) of HIV, other viruses (HBV, HBV in development) and other diseases where genetic instability may be a cause for therapy resistance (cancer, autoimmune diseases, gene therapy in development)

    Additionally, InPheno also provides a genotypic analysis - GenoTect - of the infected sample using standard procedures and protocols, to better understand the underlying genetic setup of a given resistance profile, therefore complementing the knowledge coming from the phenotypic resistance profile.